SAKAR HEALTHCARE: EXPANDS GLOBAL ONCOLOGY EXPORT BUSINESS 🟢

• Received 22 Marketing Authorisations (MAs) out of 190 applications submitted across global markets. • Secured approvals for 11 site variations in regulated markets, involving clients such as Accord Healthcare, Tillomed, Heumann Pharma and Generica KG. • Received approval for 2 out of 7 Certificate of European Pharmacopoeia Suitability (CEP) applications, supporting backward integration. • Developed 21 APIs in-house to strengthen its oncology manufacturing capabilities. • Commercial supplies have commenced from its API-integrated, EU GMP-approved oncology FDF manufacturing facility. • Company says its export-focused oncology business is unlikely to be affected by the proposed domestic MRP cap.

SAKAR HEALTHCARE LIMITED

← Back to feed